RecruitingChronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
You may qualify if…
- ✓ Participants must have been treated in the post-marketing setting with ≥1 infusion of lisocabtagene maraleucel used for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) within the approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA
You may not qualify if…
- ✕ Participants known to be participating in investigational studies at the time of lisocabtagene maraleucel infusion
- ✕ Patients treated with non-conforming CAR T-cell product
Where it's recruiting
Wisconsin
Milwaukee
Source: ClinicalTrials.gov · NCT06788639 · last updated 2025-02-24